

Results of 2023 Annual General Meeting

In accordance with ASX Listing Rule 3.13.2 and section 251AA of the Corporations Act 2001 (Cth), PainChek® Ltd (ASX: PCK) (“PainChek®” or “the Company”), developer of the world’s first smart phone-based pain assessment and monitoring application, advises the results of its 2023 Annual General Meeting held today.

All resolutions were carried and decided by way of a poll. Details of the resolutions, the proxies, and the votes cast on the poll in respect of each resolution are set out in the attached results.

This release has been authorised for release by PainChek’s Board of Directors.

For more information:

Lisa Dadswell

Company Secretary, PainChek

lisa.dadswell@boardroomlimited.com.au

02 8016 2819

Philip Daffas

CEO, PainChek

philip.daffas@painchek.com

0406 537 235

About PainChek®

PainChek® Ltd is an Australian based company that develops pain assessment technologies.

Pain often goes unrecognised and under-treated in people with communication difficulties. PainChek Universal is a clinically validated smartphone-based medical device that enables best practice pain assessment for all people, everywhere.

PainChek Universal is a complete point-of-care solution that combines the existing PainChek® App with the Numerical Rating Scale (NRS). This enables best-practice pain management for all residents living with pain in any environment — from those who cannot verbalise pain to those who can, and those who fluctuate between the two.

The PainChek® App uses artificial intelligence and facial recognition to detect pain in those who cannot self-report. This gives a voice to those who cannot verbalise pain, whilst also driving objectivity and consistency in all assessments. For those who can self-report, PainChek Universal also includes access to the Numerical Rating Scale, a well-established standard used to document pain levels amongst these individuals. PainChek Universal also supports pain assessment using both tools at the point of care, for those people whose ability to communicate fluctuates.

PainChek® is being rolled out globally in two phases: first, PainChek® for adults who are unable to effectively verbalise their pain such as people with dementia, and second, PainChek® for infants who

have not yet learnt to speak. Both the adult and infants products have received regulatory clearance in numerous markets including Australia, Europe, UK, NZ, Singapore and Canada.

The PainChek® Shared Care Program is a PainChek® licensing model which enables a professional carer to share their resident or patient data securely with other healthcare professionals or designated homebased family carers for ongoing pain assessments or clinical data review.

To find out more, visit www.painchek.com

PainChek Ltd
Annual General Meeting
Wednesday, 22 November 2023
Results of Meeting

The following information is provided in accordance with section 251AA(2) of the Corporations Act 2001 (Cth) and ASX Listing Rule 3.13.2.

Resolution details		Instructions given to validly appointed proxies (as at proxy close)				Number of votes cast on the poll (where applicable)			Resolution Result	If s250U applies
Resolution	Resolution Type	For	Against	Proxy's Discretion	Abstain	For	Against	Abstain*	Carried / Not Carried	
1. Adoption of Remuneration Report	Ordinary	77,348,555 64.98%	2,208,048 1.85%	39,490,279 33.17%	1,241,478	116,838,834 98.15%	2,208,048 1.85%	1,241,478	Carried	No
2. Re-Election of Mr Ross Harricks as a Director	Ordinary	112,199,467 39.01%	1,534,626 0.53%	173,875,745 60.46%	8,670,404	286,075,212 99.47%	1,534,626 0.53%	8,670,404	Carried	N/A
3. Re-Election of Mr John Murray as a Director	Ordinary	81,254,469 27.51%	39,537,751 13.38%	174,606,981 59.11%	881,041	255,861,450 86.62%	39,537,751 13.38%	881,041	Carried	N/A
4. Approval of 10% Placement Capacity (special resolution)	Special	118,102,621 39.95%	3,670,037 1.24%	173,880,214 58.81%	627,370	291,982,835 98.76%	3,670,037 1.24%	627,370	Carried	N/A
5. Ratification of Prior Issue of Tranche 1 Placement Shares	Ordinary	87,281,960 33.11%	2,448,150 0.93%	173,899,086 65.96%	763,216	261,181,046 99.07%	2,448,150 0.93%	763,216	Carried	N/A
6. Approval to Issue Tranche 2 Placement Shares to Director John Murray	Ordinary	79,811,210 28.51%	41,928,544 14.98%	158,194,690 56.51%	658,216	238,005,900 85.02%	41,928,544 14.98%	658,216	Carried	N/A
7. Approval to Issue Tranche 2 Placement Shares to Director Philip Daffas	Ordinary	59,294,507 21.63%	40,965,687 14.94%	173,887,272 63.43%	22,132,776	233,181,779 85.06%	40,965,687 14.94%	22,132,776	Carried	N/A
8. Approval to Issue Tranche 2 Placement Shares to Director Ross Harricks	Ordinary	71,977,917 25.01%	41,968,044 14.58%	173,882,272 60.41%	8,452,009	245,860,189 85.42%	41,968,044 14.58%	8,452,009	Carried	N/A
9. Approval to Issue Tranche 2 Placement Shares to Director Cynthia Payne	Ordinary	79,130,534 26.82%	41,978,544 14.23%	173,887,272 58.95%	1,283,892	253,017,806 85.77%	41,978,544 14.23%	1,283,892	Carried	N/A
10. Approval to Issue Tranche 2 Placement Shares to Director Adam Davey	Ordinary	68,414,614 24.08%	41,808,544 14.72%	173,887,272 61.20%	12,169,812	242,301,886 85.28%	41,808,544 14.72%	12,169,812	Carried	N/A
11. Approval of Long-Term Incentive Plan	Ordinary	77,643,061 32.68%	1,650,089 0.69%	158,333,810 66.63%	34,397,556	235,976,871 99.31%	1,650,089 0.69%	34,397,556	Carried	N/A

* Votes cast by a person who abstains on an item are not counted in calculating the required majority on a poll.